Your browser doesn't support javascript.
loading
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease.
Delvenne, Aurore; Gobom, Johan; Schindler, Suzanne E; Kate, Mara Ten; Reus, Lianne M; Dobricic, Valerija; Tijms, Betty M; Benzinger, Tammie L S; Cruchaga, Carlos; Teunissen, Charlotte E; Ramakers, Inez; Martinez-Lage, Pablo; Tainta, Mikel; Vandenberghe, Rik; Schaeverbeke, Jolien; Engelborghs, Sebastiaan; Roeck, Ellen De; Popp, Julius; Peyratout, Gwendoline; Tsolaki, Magda; Freund-Levi, Yvonne; Lovestone, Simon; Streffer, Johannes; Barkhof, Frederik; Bertram, Lars; Blennow, Kaj; Zetterberg, Henrik; Visser, Pieter Jelle; Vos, Stephanie J B.
Affiliation
  • Delvenne A; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Gobom J; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Schindler SE; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Kate MT; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Reus LM; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Dobricic V; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Tijms BM; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Benzinger TLS; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Cruchaga C; Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.
  • Teunissen CE; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Ramakers I; Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Martinez-Lage P; Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Tainta M; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers (AUMC), Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Vandenberghe R; Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Schaeverbeke J; Fundación CITA-Alzhéimer Fundazioa, Donostia, Spain.
  • Engelborghs S; Fundación CITA-Alzhéimer Fundazioa, Donostia, Spain.
  • Roeck E; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Popp J; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Peyratout G; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Tsolaki M; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
  • Freund-Levi Y; Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Lovestone S; Department of Neurology and Bru-BRAIN, Universitair Ziekenhuis Brussel and NEUR Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Brussels, Belgium.
  • Streffer J; Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Barkhof F; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
  • Bertram L; Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland.
  • Blennow K; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatry University Hospital Zürich, Zürich, Switzerland.
  • Zetterberg H; Old Age Psychiatry, University Hospital Lausanne, Lausanne, Switzerland.
  • Visser PJ; 1st Department of Neurology, AHEPA University Hospital, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece.
  • Vos SJB; Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Stockholm, Sweden.
Alzheimers Dement ; 2024 Jul 06.
Article de En | MEDLINE | ID: mdl-38970402
ABSTRACT

INTRODUCTION:

We aimed to unravel the underlying pathophysiology of the neurodegeneration (N) markers neurogranin (Ng), neurofilament light (NfL), and hippocampal volume (HCV), in Alzheimer's disease (AD) using cerebrospinal fluid (CSF) proteomics.

METHODS:

Individuals without dementia were classified as A+ (CSF amyloid beta [Aß]42), T+ (CSF phosphorylated tau181), and N+ or N- based on Ng, NfL, or HCV separately. CSF proteomics were generated and compared between groups using analysis of covariance.

RESULTS:

Only a few individuals were A+T+Ng-. A+T+Ng+ and A+T+NfL+ showed different proteomic profiles compared to A+T+Ng- and A+T+NfL-, respectively. Both Ng+ and NfL+ were associated with neuroplasticity, though in opposite directions. Compared to A+T+HCV-, A+T+HCV+ showed few proteomic changes, associated with oxidative stress.

DISCUSSION:

Different N markers are associated with distinct neurodegenerative processes and should not be equated. N markers may differentially complement disease staging beyond amyloid and tau. Our findings suggest that Ng may not be an optimal N marker, given its low incongruency with tau pathophysiology. HIGHLIGHTS In Alzheimer's disease, neurogranin (Ng)+, neurofilament light (NfL)+, and hippocampal volume (HCV)+ showed differential protein expression in cerebrospinal fluid. Ng+ and NfL+ were associated with neuroplasticity, although in opposite directions. HCV+ showed few proteomic changes, related to oxidative stress. Neurodegeneration (N) markers may differentially refine disease staging beyond amyloid and tau. Ng might not be an optimal N marker, as it relates more closely to tau.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Alzheimers Dement Année: 2024 Type de document: Article Pays d'affiliation: Pays-Bas

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Alzheimers Dement Année: 2024 Type de document: Article Pays d'affiliation: Pays-Bas
...